These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 36355761)

  • 21. DIAGNOSTIC ACCURACY OF THE NON-INVASIVE MARKERS NFLS, NI-NASH-DS, AND FIB-4 FOR ASSESSMENT OF DIFFERENT ASPECTS OF NON-ALCOHOLIC FATTY LIVER DISEASE IN INDIVIDUALS WITH OBESITY: CROSS-SECTIONAL STUDY.
    Haddad GM; Gestic MA; Utrini MP; Chaim FDM; Chaim EA; Cazzo E
    Arq Gastroenterol; 2024; 61():e23050. PubMed ID: 38896571
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MRE combined with FIB-4 (MEFIB) index in detection of candidates for pharmacological treatment of NASH-related fibrosis.
    Jung J; Loomba RR; Imajo K; Madamba E; Gandhi S; Bettencourt R; Singh S; Hernandez C; Valasek MA; Behling C; Richards L; Fowler K; Sirlin CB; Nakajima A; Loomba R
    Gut; 2021 Oct; 70(10):1946-1953. PubMed ID: 33214165
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers.
    Vilar-Gomez E; Chalasani N
    J Hepatol; 2018 Feb; 68(2):305-315. PubMed ID: 29154965
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum cytokeratin-18 fragment levels as noninvasive marker of nonalcoholic steatohepatitis in the chilean population.
    Arab JP; Hernández-Rocha C; Morales C; Vargas JI; Solís N; Pizarro M; Robles C; Sandoval D; Ponthus S; Benítez C; Barrera F; Soza A; Riquelme A; Arrese M
    Gastroenterol Hepatol; 2017; 40(6):388-394. PubMed ID: 28359548
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Stratifying Non-alcoholic Steatohepatitis With the Non-invasive Ultrasound Markers Shear Wave Dispersion Slope and Shear Wave Velocity: An Animal Study.
    Kong W; Tang Y; Liu L; Zhang G; Liu Y; Liu J
    Ultrasound Med Biol; 2022 Dec; 48(12):2442-2448. PubMed ID: 36096895
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluating M2BPGi as a Marker for Liver Fibrosis in Patients with Chronic Hepatitis B.
    Bui HH; Nguyen ST; Phan ST; Nguyen KM; Nguyen CD
    Dig Dis Sci; 2023 Dec; 68(12):4407-4417. PubMed ID: 37861877
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The combination of the enhanced liver fibrosis and FIB-4 scores to determine significant fibrosis in patients with nonalcoholic fatty liver disease.
    Younossi ZM; Stepanova M; Felix S; Jeffers T; Younossi E; Goodman Z; Racila A; Lam BP; Henry L
    Aliment Pharmacol Ther; 2023 Jun; 57(12):1417-1422. PubMed ID: 36967586
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of ballooned hepatocytes as a risk factor for future progression of fibrosis in patients with non-alcoholic fatty liver disease.
    Kakisaka K; Suzuki Y; Fujiwara Y; Abe T; Yonezawa M; Kuroda H; Ishida K; Sugai T; Takikawa Y
    J Gastroenterol; 2018 Dec; 53(12):1285-1291. PubMed ID: 29680867
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diagnostic Accuracy of Noninvasive Fibrosis Models to Detect Change in Fibrosis Stage.
    Siddiqui MS; Yamada G; Vuppalanchi R; Van Natta M; Loomba R; Guy C; Brandman D; Tonascia J; Chalasani N; Neuschwander-Tetri B; Sanyal AJ;
    Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1877-1885.e5. PubMed ID: 30616027
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Accuracy of Noninvasive Fibrosis Scores to Detect Advanced Fibrosis in Patients With Type-2 Diabetes With Biopsy-proven Nonalcoholic Fatty Liver Disease.
    Singh A; Gosai F; Siddiqui MT; Gupta M; Lopez R; Lawitz E; Poordad F; Carey W; McCullough A; Alkhouri N
    J Clin Gastroenterol; 2020; 54(10):891-897. PubMed ID: 32168133
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A simple scoring system using type IV collagen 7S and aspartate aminotransferase for diagnosing nonalcoholic steatohepatitis and related fibrosis.
    Okanoue T; Ebise H; Kai T; Mizuno M; Shima T; Ichihara J; Aoki M
    J Gastroenterol; 2018 Jan; 53(1):129-139. PubMed ID: 28589339
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relationship between three commonly used non-invasive fibrosis biomarkers and improvement in fibrosis stage in patients with non-alcoholic steatohepatitis.
    Chalasani N; Abdelmalek MF; Loomba R; Kowdley KV; McCullough AJ; Dasarathy S; Neuschwander-Tetri BA; Terrault N; Ferguson B; Shringarpure R; Shapiro D; Sanyal AJ
    Liver Int; 2019 May; 39(5):924-932. PubMed ID: 30253043
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of non-invasive parameters of non-alcoholic steatohepatitis and liver fibrosis in daily practice--an exploratory case-control study.
    Dvorak K; Stritesky J; Petrtyl J; Vitek L; Sroubkova R; Lenicek M; Smid V; Haluzik M; Bruha R
    PLoS One; 2014; 9(10):e111551. PubMed ID: 25350286
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sequential Combination of FIB-4 Followed by M2BPGi Enhanced Diagnostic Performance for Advanced Hepatic Fibrosis in an Average Risk Population.
    Kim M; Jun DW; Park H; Kang BK; Sumida Y
    J Clin Med; 2020 Apr; 9(4):. PubMed ID: 32295166
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of ADAPT, FIB-4 and APRI as non-invasive predictors of liver fibrosis and NASH within the CENTAUR screening population.
    Nielsen MJ; Leeming DJ; Goodman Z; Friedman S; Frederiksen P; Rasmussen DGK; Vig P; Seyedkazemi S; Fischer L; Torstenson R; Karsdal MA; Lefebvre E; Sanyal AJ; Ratziu V
    J Hepatol; 2021 Dec; 75(6):1292-1300. PubMed ID: 34454994
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessment of liver fibrosis using non-invasive screening tools in individuals with diabetes mellitus and metabolic syndrome.
    Shaji N; Singhai A; Joshi R
    J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443467
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis.
    Noureddin M; Truong E; Gornbein JA; Saouaf R; Guindi M; Todo T; Noureddin N; Yang JD; Harrison SA; Alkhouri N
    J Hepatol; 2022 Apr; 76(4):781-787. PubMed ID: 34798176
    [TBL] [Abstract][Full Text] [Related]  

  • 38. M2BPGi for assessing liver fibrosis in patients with hepatitis C treated with direct-acting antivirals.
    Saleh SA; Salama MM; Alhusseini MM; Mohamed GA
    World J Gastroenterol; 2020 Jun; 26(21):2864-2876. PubMed ID: 32550761
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hepatokine-based identification of fibrotic NASH and improved risk stratification in a multicentre cohort of NAFLD patients.
    Franck M; John K; Al Aoua S; Rau M; Geier A; Schattenberg JM; Wedemeyer H; Schulze-Osthoff K; Bantel H
    Liver Int; 2023 Dec; 43(12):2668-2679. PubMed ID: 37534777
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence, Diagnosis, and Treatment with 3 Different Statins of Non-alcoholic Fatty Liver Disease/Non-alcoholic Steatohepatitis in Military Personnel. Do Genetics Play a Role?
    Sfikas G; Psallas M; Koumaras C; Imprialos K; Perdikakis E; Doumas M; Giouleme O; Karagiannis A; Athyros VG
    Curr Vasc Pharmacol; 2021; 19(5):572-581. PubMed ID: 33059580
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.